| pubmed-article:8252745 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:8252745 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:8252745 | lifeskim:mentions | umls-concept:C0032105 | lld:lifeskim |
| pubmed-article:8252745 | lifeskim:mentions | umls-concept:C0035094 | lld:lifeskim |
| pubmed-article:8252745 | lifeskim:mentions | umls-concept:C0085580 | lld:lifeskim |
| pubmed-article:8252745 | lifeskim:mentions | umls-concept:C0205250 | lld:lifeskim |
| pubmed-article:8252745 | lifeskim:mentions | umls-concept:C0045052 | lld:lifeskim |
| pubmed-article:8252745 | pubmed:issue | 5 | lld:pubmed |
| pubmed-article:8252745 | pubmed:dateCreated | 1994-1-10 | lld:pubmed |
| pubmed-article:8252745 | pubmed:abstractText | We have reported that 19-hydroxyandrostenedione (19-OH-A-dione) functions as an amplifier of the sodium-retaining and hypertensive action of aldosterone. We therefore measured 19-hydroxyandrostenedione in hypertensive patients. | lld:pubmed |
| pubmed-article:8252745 | pubmed:language | eng | lld:pubmed |
| pubmed-article:8252745 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8252745 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:8252745 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8252745 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8252745 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:8252745 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:8252745 | pubmed:month | Nov | lld:pubmed |
| pubmed-article:8252745 | pubmed:issn | 0300-0664 | lld:pubmed |
| pubmed-article:8252745 | pubmed:author | pubmed-author:YazakiYY | lld:pubmed |
| pubmed-article:8252745 | pubmed:author | pubmed-author:CoyerJ RJR | lld:pubmed |
| pubmed-article:8252745 | pubmed:author | pubmed-author:SekiharaHH | lld:pubmed |
| pubmed-article:8252745 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:8252745 | pubmed:volume | 39 | lld:pubmed |
| pubmed-article:8252745 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:8252745 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:8252745 | pubmed:pagination | 557-60 | lld:pubmed |
| pubmed-article:8252745 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:8252745 | pubmed:meshHeading | pubmed-meshheading:8252745-... | lld:pubmed |
| pubmed-article:8252745 | pubmed:meshHeading | pubmed-meshheading:8252745-... | lld:pubmed |
| pubmed-article:8252745 | pubmed:meshHeading | pubmed-meshheading:8252745-... | lld:pubmed |
| pubmed-article:8252745 | pubmed:meshHeading | pubmed-meshheading:8252745-... | lld:pubmed |
| pubmed-article:8252745 | pubmed:meshHeading | pubmed-meshheading:8252745-... | lld:pubmed |
| pubmed-article:8252745 | pubmed:meshHeading | pubmed-meshheading:8252745-... | lld:pubmed |
| pubmed-article:8252745 | pubmed:meshHeading | pubmed-meshheading:8252745-... | lld:pubmed |
| pubmed-article:8252745 | pubmed:meshHeading | pubmed-meshheading:8252745-... | lld:pubmed |
| pubmed-article:8252745 | pubmed:year | 1993 | lld:pubmed |
| pubmed-article:8252745 | pubmed:articleTitle | Plasma 19-hydroxyandrostenedione is elevated in patients with high renin essential hypertension. | lld:pubmed |
| pubmed-article:8252745 | pubmed:affiliation | Third Department of Internal Medicine, University of Tokyo Faculty of Medicine, Japan. | lld:pubmed |
| pubmed-article:8252745 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:8252745 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:8252745 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
